Benjamin McDonald
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
Year:
2026
Year:
2026
INTRODUCTION: Janus kinase inhibitors (JAKi) are small-molecule therapies used in inflammatory bowel disease (IBD). We describe 8 patients with IBD who developed an eczematous eruption, presumed atopic dermatitis (AD), after stopping JAKi therapy. METHODS: This case series describes 8 patients with IBD who developed de novo AD after withdrawal of JAKi therapy. RESULTS: Median time to AD onset was 7 days (interquartile range 2–12). Two cases with biopsy-confirmed AD resolved after reinitiation of JAKi therapy and adjunct AD treatments. DISCUSSION: A subset of patients with IBD may have latent susceptibility to AD, unmasked by therapy cessation and potentially triggered by an immune rebound effect.
Year:
2025
Year:
2024
Year:
2022
Collaborators (6)
Alex J Mathew
Research Director (Rubin Lab)
University of Chicago
David Choi
University of Chicago Medicine
Angad Chadha
Physician / Asst Prof
University of Chicago
Christopher Shea
Professor
University of Chicago
Joel Pekow
-
David Rubin
Professor
University of Chicago
Make your next move.
Prepare your application
Review drafts before you send them.